Taken together, KChIP3 (calsenilin) with its target proteins PS1 and PS2 plays a critical role in both APP γ-cleavage and ER Ca2+ release, functions which are dysregulated in Alzheimer’s disease [53]. Here, APP is linked to Alzheimer disease.